Piperacillin‑tazobactam‑induced myocardial injury with heart failure: A case report

Liu,Yi; An,Chuan; Ai,Xin; Zhang,Xinyu; Shi,Lin; Zhao,Quanlin

doi:10.3892/etm.2024.12393

Piperacillin‑tazobactam‑induced myocardial injury with heart failure: A case report

Authors:
- Yi Liu
- Chuan An
- Xin Ai
- Xinyu Zhang
- Lin Shi
- Quanlin Zhao
View Affiliations

Affiliations: The First Clinical Medical College, Shandong University of Traditional Chinese Medicine, Jinan, Shandong 250014, P.R. China, Department of Integrated Internal Medicine, The Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, Shandong 250014, P.R. China
Published online on: January 17, 2024 https://doi.org/10.3892/etm.2024.12393
Article Number: 105
Copyright: © Liu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Piperacillin‑tazobactam is a clinically used antibiotic consisting of the semisynthetic penicillin piperacillin and the β‑lactamase inhibitor tazobactam. Piperacillin‑tazobactam is a broad‑spectrum antibiotic used clinically to treat infections caused by gram‑positive and gram‑negative aerobic and anaerobic bacteria. The most common adverse reactions are gastrointestinal symptoms and skin reactions. There have been a few reported cases of possible drug hypersensitivity, with thrombocytopenia as the most commonly observed adverse event. The present article reported a rare case of myocardial injury with heart failure following treatment of pneumonia with piperacillin‑tazobactam in a 75‑year‑old female patient. Specifically, this patient presented with fever, chills, flushing and tachypnea, in addition to elevated leukocyte, neutrophil, cardiac enzyme and brain natriuretic peptide levels. This patient also presented with a mild ST‑segment elevation on the electrocardiogram following piperacillin‑tazobactam treatment. Improvements in the aforementioned adverse reactions were observed and the underlying infection didn't come back following the discontinuation of piperacillin‑tazobactam treatment. Therefore, the present observations suggest that piperacillin‑tazobactam may have induced myocardial injury and heart failure. Possible occurrence of similar adverse reactions in the heart should be considered before choosing piperacillin‑tazobactam as treatment in clinical practice.

View Figures

View References

1	Gin A, Dilay L, Karlowsky JA, Walkty A, Rubinstein E and Zhanel GG: Piperacillin-tazobactam: A beta-lactam/beta-lactamase inhibitor combination. Expert Rev Anti Infect Ther. 5:365–383. 2007.PubMed/NCBI View Article : Google Scholar
2	Hayashi Y, Roberts JA, Paterson DL and Lipman J: Pharmacokinetic evaluation of piperacillin-tazobactam. Expert Opin Drug Metab Toxicol. 6:1017–1031. 2010.PubMed/NCBI View Article : Google Scholar
3	Perry CM and Markham A: Piperacillin/tazobactam: An updated review of its use in the treatment of bacterial infections. Drugs. 57:805–843. 1999.PubMed/NCBI View Article : Google Scholar
4	Linares T, Fernández A, Soto MT, Escudero E and Gacías L: Drug fever caused by piperacillin-tazobactam. J Investig Allergol Clin Immunol. 21:250–251. 2011.PubMed/NCBI
5	Wang Q, He Z, Wu X, Wei Y and Huang J: Hematologic adverse effects induced by piperacillin-tazobactam: A systematic review of case reports. Int J Clin Pharm. 42:1026–1035. 2020.PubMed/NCBI View Article : Google Scholar
6	Cabañas R, Calderon O, Ramirez E, Fiandor A, Prior N, Caballero T, Herránz P, Bobolea I, López-Serrano MC, Quirce S and Bellón T: Piperacillin-induced DRESS: distinguishing features observed in a clinical and allergy study of 8 patients. J Investig Allergol Clin Immunol. 24:425–430. 2014.PubMed/NCBI
7	Metlay JP, Waterer GW, Long AC, Anzueto A, Brozek J, Crothers K, Cooley LA, Dean NC, Fine MJ, Flanders SA, et al: Diagnosis and treatment of adults with community-acquired pneumonia. An official clinical practice guideline of the american thoracic society and infectious diseases society of America. Am J Respir Crit Care Med. 200:e45–e67. 2019.PubMed/NCBI View Article : Google Scholar
8	Gu W, Miller S and Chiu CY: Clinical metagenomic next-generation sequencing for pathogen detection. Annu Rev Pathol. 14:319–338. 2019.PubMed/NCBI View Article : Google Scholar
9	Gagnier JJ, Kienle G, Altman DG, Moher D, Sox H and Riley D: CARE Group. The CARE guidelines: Consensus-based clinical case reporting guideline development. BMJ Case Rep. 2013(bcr2013201554)2013.PubMed/NCBI View Article : Google Scholar
10	Alzahrani M, Alrumaih I, Alhamad F and Abdel Warith A: Rapid onset severe thrombocytopenia following reexposure to piperacillin-tazobactam: Report of two cases and review of the literature. Platelets. 29:628–631. 2018.PubMed/NCBI View Article : Google Scholar
11	Beaulieu C, Kurczewski L and Yajnik V: Cefepime challenge after piperacillin/tazobactam-induced thrombocytopenia. J Thromb Thrombolysis. 48:167–170. 2019.PubMed/NCBI View Article : Google Scholar
12	Bai M, Govindaraj V, Kottaisamy R and Vijayarangam N: Drug reaction with eosinophilia and systemic symptoms syndrome related to piperacillin-tazobactam use. J Postgrad Med. 68:102–105. 2022.PubMed/NCBI View Article : Google Scholar
13	Lv J, Wu G, Zhang F and Su X: An unusual case of piperacillin-tazobactam-induced fever, eosinophilia, thrombocytopenia and liver damage. Eur J Hosp Pharm Sci Pract. 29:e91–e94. 2022.PubMed/NCBI View Article : Google Scholar
14	Jafri F, Arif S and Ashraf U: Hypersensitivity myocarditis associated with piperacillin-tazobactam use. Chest. 158 (Suppl)(A226)2020.
15	Calogiuri GF, Nettis E, Di Leo E, Vacca A, Ferrannini A and Kounis NG: Kounis syndrome induced by intravenous administration of piperacillin/tazobactam: A case report. Int J Cardiol. 155:e42–e44. 2012.PubMed/NCBI View Article : Google Scholar
16	Abdelghany M, Subedi R, Shah S and Kozman H: Kounis syndrome: A review article on epidemiology, diagnostic findings, management and complications of allergic acute coronary syndrome. Int J Cardiol. 232:1–4. 2017.PubMed/NCBI View Article : Google Scholar
17	Saloojee A, Skinner DL, Loots E, Hardcastle TC and Muckart DJJ: Hepatic dysfunction: A common occurrence in severely injured patients. Injury. 48:127–132. 2017.PubMed/NCBI View Article : Google Scholar
18	McDonald C, Cotta MO, Little PJ, McWhinney B, Ungerer JP, Lipman J and Roberts JA: Is high-dose β-lactam therapy associated with excessive drug toxicity in critically ill patients? Minerva Anestesiol. 82:957–965. 2016.PubMed/NCBI
19	Aun MV, Kalil J and Giavina-Bianchi P: Drug-induced anaphylaxis. Immunol Allergy Clin North Am. 37:629–641. 2017.PubMed/NCBI View Article : Google Scholar
20	Bhattacharyya S, Darby RR, Raibagkar P, Gonzalez Castro LN and Berkowitz AL: Antibiotic-associated encephalopathy. Neurology. 86:963–971. 2016.PubMed/NCBI View Article : Google Scholar